Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 5,960 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert Goeltz II sold 5,960 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $132,073.60. Following the sale, the chief financial officer owned 74,476 shares of the company’s stock, valued at approximately $1,650,388.16. The trade was a 7.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Arcus Biosciences Trading Down 1.2%

NYSE:RCUS traded down $0.26 on Thursday, hitting $22.02. 1,175,874 shares of the stock were exchanged, compared to its average volume of 1,200,446. The stock has a fifty day moving average of $20.82 and a 200-day moving average of $13.98. The stock has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $26.40.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. During the same quarter in the prior year, the company earned ($1.00) EPS. The company’s revenue was down 45.8% on a year-over-year basis. As a group, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the topic of a number of research reports. HC Wainwright raised their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Wedbush set a $35.00 price target on Arcus Biosciences and gave the company an “outperform” rating in a report on Wednesday, October 29th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday. Bank of America upped their target price on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Finally, Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. raised its position in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares in the last quarter. CWM LLC raised its position in shares of Arcus Biosciences by 233.6% in the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after purchasing an additional 3,810 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Arcus Biosciences by 34.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after buying an additional 1,796 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Arcus Biosciences by 440.3% during the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after buying an additional 6,191 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.